Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.
The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.
Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.
Serum antibodies precede the development of clinical rheumatoid arthritis (RAby) by many years, and yet we still have much to learn about this preclinical phase.
Researchers from the University of British Columbia reported on their systematic review and meta-analysis of risk of herpes zoster (HZ) in patients receiving biologics, DMARDs and/or corticosteroids for autoimmune diseases.
A recent article published by the American Academy of Ophthalmology (AAO) presented new recommendations for screening of patients being managed with hydroxychloroquine (HCQ).
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
